The European Commission has approved dostarlimab in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary…
Ana Oaknin
Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific…
The phase 2 multicenter TROPION-PanTumor study was designed to evaluate the efficacy of TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) as…
Published in The Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint…
Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data…
Results of long-term survival analysis of the phase III EMPOWER-Cervical 1 multicenter clinical trial show that immune checkpoint inhibitor cemiplimab…
Now published in the European Society for Medical Oncology’s (ESMO) flagship journal, Annals of Oncology, ESMO’s Clinical Practice Guideline for…
Published last week in Nature Reviews Disease Primers, a comprehensive review* focused on endometrial cancer (EC) updates on the epidemiology,…
Barcelona, May 12, 2021- Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death…
In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…
